FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
30.0 puan (24s)Health & MedicineOne-Off3ay
KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiOrta düzey kalibreGüncel ima edilen olasılık
Evet 97%+30.0pt
Piyasa kalitesi
45 / 100
Düşük kalite24s Hacim
₺30,4 B
Likidite
₺33,5 B
Düşük likiditeAlış / Satış
72.0% / 80.0%
Spread
8.0 pt
Geniş spreadPiyasa verileri
8 dakika önce güncellendi
17 Haz 26 21:30 UTC1 Oca 27 04:59 UTC
Trendler
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketKurallar
If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Uzlaşma kaynağı:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
- Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
- In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.
Açık piyasalar
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Toplam Hacim
- ₺876,3 Mn
- 24s Hacim
- ₺1 Mn
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Toplam Hacim
- ₺91,4 Mn
- 24s Hacim
- ₺291,7 B
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 daha fazla sonuç
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Toplam Hacim
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Toplam Hacim
- ₺51,6 Mn
- 24s Hacim
- ₺85,3 B
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000+1.0pt60%
+2 daha fazla sonuç
- Toplam Hacim
- ₺48,6 Mn
- 24s Hacim
- ₺58,5 B
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Sık sorulan sorular
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) için güncel oranlar nedir?
- Kalshi, 8 Eylül 2026 itibarıyla Yes için 97% fiyatlıyor.
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) ne zaman sonuçlanacak?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) için öngörülen sonuçlanma tarihi 1 Ocak 2027.
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) nasıl sonuçlandırılıyor?
- Kalshi bu piyasayı şu şekilde sonuçlandırır: If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.